IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Drug Therapy In Congestive Heart Failure: A Review Article

Corresponding author: Dr.Vanita B. Wadewale

Assistant professor

Department: pharmacy practice

Ashwini Patmas[1], Narhare vaishnavi[2],

Pharm D 2nd year

Pharmacy practice

Shivlingeshwar College of Pharmacy, Almala, dist. Latur, Maharashtra .

Abstract

Congestive Heart Failure (CHF) remains one of the leading causes of morbidity and mortality worldwide.

It represents a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection of blood.

The primary goal of drug therapy is to improve survival, reduce hospitalizations, and enhance the quality of life.

Pharmacotherapy for CHF includes several classes of drugs such as ACE inhibitors ARBs: improve survival by suppressing renin angiotensin aldosterone system .beta blocker: reduce sympathetic overactivity And improve long –term survival .

SGLT2 inhibitors: diuretics first-line for symptomatic relief of congestion ,ivabradine benefits selected patients with high resting heart rate . and novel agents like ARNIs and Vericiguat. This review summarizes the current understanding, mechanisms,

And rational drug therapy depends on functional class (NYHA),the combination of guideline-directed medical therapy (GDMT)has singnificantly transformed CHF prognosis , shifting for CHF management.

Keywords

Congestive Heart Failure, Drug Therapy, Pharmacological Management, SGLT2 Inhibitors, Guideline-Directed Medical Therapy, Beta-Blockers.

Introduction

Congestive Heart Failure (CHF) is a chronic progressive condition characterized by the inability of the heart to pump

Blood efficiently to meet the body's metabolic demands. It is classified based on ejection fraction as Heart Failure

With Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF). The condition is associated with high morbidity, mortality, and healthcare costs. Over the past few decades, advances in drug therapy

Have significantly improved clinical outcomes in patients with CHF.

It represent the final common pathway of various cardiovascular disorder such as ischemic heart disease , long standing hypertension , valvular abnormalities , and cardiomyopathies . globally ,CHF is a major health burden affecting more than 64 million individuals.

CHF is the most commom reason for hospitalization in the united states for people aged 65 years and older , with more than 1 million patients admitted for this condition each year approximately 300,000 deaths each year can be attributed to CHF.

Pathophysiology

Recent advances have enhanced the understanding of the underlying mechanisms of acute decompensated heart failure (ADHF). Traditionally, ADHF has been described as a consequence of preexisting systolic dysfunction combined with progressive fluid accumulation. However, studies indicate that a large proportion of patients presenting to the emergency department (ED) with ADHF actually have preserved systolic function and are not significantly volume overloaded.

In most acutely decompensated cases, the clinical picture is influenced by more complex physiological disturbances rather than simple intravascular volume excess. These disturbances can broadly be categorized into cardiac failure and vascular failure.

1. **Cardiac Failure:**

This type reflects the conventional concept of ADHF, where a patient with chronic heart failure experiences volume overload due to factors such as medication noncompliance, dietary indiscretion, or acute renal impairment. Because the heart is structurally and functionally weakened, it cannot handle additional preload, resulting in pulmonary congestion and peripheral edema. The clinical manifestations in these patients typically progress gradually over time.

2. **Vascular Failure:**

In contrast, vascular failure involves a sudden increase in vascular tone and afterload, leading to rapid decompensation. This abrupt hemodynamic change is primarily mediated through neurohormonal activation, particularly of the sympathetic nervous system and the renin–angiotensin–aldosterone system (RAAS). Patients with vascular failure usually develop symptoms suddenly, often without peripheral edema, and generally maintain normal systolic function. They commonly present to the ED in a hypertensive state and may appear either euvolemic or mildly hypovolemic.

Classification

The European Society of Cardiology has classified acute heart failure into distinct Clinical syndromes (Box 1).6,7 Some patients present with overlapping features, but Their appropriate classification is important, because each requires a specific thera-Peutic approach.

Box 1
Classification of acute heart failure

- Acute decompensated heart failure
- Hypertensive acute heart failure
- Pulmonary edema
- Cardiogenic shock
- Right heart failure
- Acute coronary syndrome complicated by acute heart failure

Adapted from Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute heart failure 2008. Eur J Heart Fail 2008;10:968.

Symptoms and signs

(what patient feels)

Dyspnea (shortness of breath) – on exertion → at rest

Orthopnea – breathlessness while lying flat

Paroxysmal Nocturnal Dyspnea (PND) – sudden night breathlessness

Fatigue & weakness

Exercise intolerance

Cough (especially at night)

Chest discomfort / palpitations

Nocturia (frequent urination at night)

Loss of appetite / nausea

(what doctor detects)

Left sided failure signs:

Tachycardia (↑ HR)

Tachypnea (↑ RR)

Pulmonary rales / crackles on auscultation

S3 gallop sound

Cyanosis (in severe cases)

Right sided failure signs:

Peripheral edema (swelling in legs, ankles)

Hepatomegaly (enlarged liver)

Ascites (fluid in abdomen)

Jugular venous distention (JVD)

Weight gain (fluid retention)

General signs seen in both:

Reduced BP (hypotension in severe HF)

Cold extremities (poor perfusion)

Pharmacological Management of CHF

The pharmacological treatment of CHF aims to modulate neurohormonal activation, improve cardiac output, And prevent disease progression. The major classes of drugs include:

1.ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

ACE inhibitors such as Enalapril and Lisinopril inhibit the conversion of angiotensin I to angiotensin II, Leading to vasodilation, decreased aldosterone secretion, and reduced cardiac remodeling. The CONSENSUS and SOLVD

Trials demonstrated a significant reduction in mortality with ACE inhibitors in CHF patients.

2.Beta-Blockers

Beta-blockers like Carvedilol, Bisoprolol, and Metoprolol succinate reduce sympathetic nervous system activation, Decrease heart rate, and improve survival. The COPERNICUS and MERIT-HF trials confirmed their beneficial effects In reducing mortality and hospitalization.

3.Angiotensin II Receptor Blockers (ARBs)

ARBs such as Losartan and Valsartan are used as alternatives to ACE inhibitors in patients intolerant to cough or angioedema.

The ELITE II trial showed comparable efficacy between Losartan and Captopril.

4.Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone and Eplerenone inhibit aldosterone, reducing sodium retention and fibrosis. The RALES and EMPHASIS-HF Trials demonstrated a marked reduction in mortality and hospitalization rates.

5.Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) Sacubitril/Valsartan, a combination of neprilysin inhibitor and ARB, enhances natriuretic peptide activity while Blocking angiotensin II. The PARADIGM-HF trial showed superior compared to Enalapril.

6.-Glucose Co-Transporter 2 (SGLT2) Inhibitors

Originally used as antidiabetic agents, SGLT2 inhibitors such as Dapagliflozin and Empagliflozin have shown Remarkable benefits in CHF patients, independent of diabetic status. The DAPA-HF and EMPEROR-Reduced trials confirmed Reductions in hospitalization and cardiovascular death.

7.Other Novel Agents

Newer agents like Vericiguat (a soluble guanylate cyclase stimulator) and Omecamtiv Mecarbil (a myosin activator) Have shown promise in patients with advanced heart failure. The VICTORIA and GALACTIC-HF trials hig Sodium hlight their Potential role in GDMT.

Conclusion

Comprehensive pharmacotherapy remains the cornerstone in the management of CHF.

Recent advances such as SGLT2 inhibitors and ARNIs have revolutionized patient outcomes.

Future perspectives focus on precision medicine and optimizing guideline-directed therapy for individualized care.

References

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421.
3. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995–2008.
4. Packer M, Coats AJS, Fowler MB, et al. Effect of Carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658.

5. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709–717.
6. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
7. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424.
8. Swedberg K, Kjekshus J, Snapinn S. Effects of enalapril on mortality in severe congestive heart failure: CONSENSUS trial. N Engl J Med. 1987;316:1429–1435.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions. N Engl J Med. 1991;325:293–302.
10. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in CHF: ELITE II study. Lancet. 2000;355:1582–1587.
11. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms (EMPHASIS-HF). N Engl J Med. 2011;364:11–21.
12. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction (VICTORIA trial). N Engl J Med. 2020;382:1883–1893.
13. Teerlink JR, Felker GM, McMurray JJV, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction (GALACTIC-HF). N Engl J Med. 2021;384:105–116.
14. Lam CSP, Voors AA, de Boer RA, et al. Heart failure with preserved ejection fraction: current understanding and future directions. Eur Heart J. 2018;39(11):1107–1119.
15. Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure. Lancet. 2020;396:121–128.